Octreotide + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Kidney, Autosomal Dominant
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Trial Timeline
Jan 1, 2007 → Oct 1, 2008
NCT ID
NCT00426153About Octreotide + Placebo
Octreotide + Placebo is a phase 2/3 stage product being developed by Novartis for Polycystic Kidney, Autosomal Dominant. The current trial status is completed. This product is registered under clinical trial identifier NCT00426153. Target conditions include Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00426153 | Phase 2/3 | Completed |
| NCT00399893 | Pre-clinical | Terminated |
Competing Products
20 competing products in Polycystic Kidney, Autosomal Dominant